This article is more than 5 years old. Information may no longer be current.
IOP reduction, medication elimination noted after implantation of two iStent inject devices
Click Here to Manage Email Alerts
Patients with open-angle glaucoma had an IOP reduction in phakic eyes with the elimination of medication through 18 months after undergoing standalone implantation of two iStent inject devices, according to a study.
Researchers included 57 phakic eyes with open-angle glaucoma in the prospective, open-label, single-arm study conducted in Armenia. Preoperatively, each subject had a medicated IOP of 18 mm Hg to 30 mm Hg on one topical ocular hypotensive medication and an unmedicated IOP of 22 mm Hg to 38 mm Hg.
Each patient underwent implantation of two second-generation iStent inject trabecular micro-bypass stents (Glaukos) in a standalone procedure.
At 12 months postop, all eyes had an IOP reduction of 20% or more without medication vs. the preoperative unmedicated IOP. Additionally, 75% of patients had an IOP reduction of 20% or more without medication vs. the preoperative medicated IOP.
Postoperatively, one subject in the cohort had a pre-existing cataract progress with best corrected visual acuity loss of more than one line. The remaining subjects had stable BCVA at month 18. There were no intraoperative and device-related adverse events.
“This study collected valuable data in a stable cohort with excellent accountability through 18 months, and follow-up is ongoing. The results confirm that IOP reduction to 15 mm Hg [or less] with elimination of medication — and a favorable safety profile — is possible after the standalone implantation of two iStent inject devices in OAG eyes with IOP not managed to below 18 mm Hg on one preoperative medication,” the study authors said.
Disclosure: Lindstrom reports he is a consultant for and stockholder of Glaukos. Please see the full study for a list of all other authors’ relevant financial disclosures.
Click Here to Manage Email Alerts